Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H40N2 |
Molecular Weight | 356.5878 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CC[C@@]3([H])[C@]4([H])CC=C5C[C@H](CC[C@]5(C)[C@@]4([H])CC[C@]13CN(C)[C@H]2C)N(C)C
InChI
InChIKey=GPLGAQQQNWMVMM-MYAJQUOBSA-N
InChI=1S/C24H40N2/c1-16-20-8-9-22-19-7-6-17-14-18(25(3)4)10-12-23(17,2)21(19)11-13-24(20,22)15-26(16)5/h6,16,18-22H,7-15H2,1-5H3/t16-,18-,19+,20+,21-,22-,23-,24-/m0/s1
Conessine is a plant steroid alkaloid that acts as a potent and specific antagonist of histamine H3 receptors. Conessine displayed high affinity at both rat and human H3 receptors (pKi = 7.61 and 8.27) and generally high selectivity against other sites, including histamine receptors H1, H2, and H4. Conessine was found to efficiently penetrate the CNS and reach very high brain concentrations. Although the very slow CNS clearance and strong binding to adrenergic receptors discouraged focus on conessine itself for further development, its potency and novel steroid-based skeleton motivated further chemical investigation. Modification based on introducing diversity at the 3-nitrogen position generated a new series of H3 antagonists with higher in vitro potency, improved target selectivity, and more favorable drug-like properties. Conessine also has high affinity for the adrenergic receptors. Conessine has being shown to possess anti-malarial activity. In India conessine finds therapeutic use for treatment of dysentery and helminthic disorders.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL264 |
8.27 null [pKi] | ||
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18683917 |
6.18 null [pKi] | ||
Target ID: CHEMBL364 |
1.04 µM [IC50] | ||
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22569298 |
21.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Squalamine: an aminosterol antibiotic from the shark. | 1993 Feb 15 |
|
Déjà vu guides the way to new antimicrobial steroid. | 1993 Feb 19 |
|
Steroid hormone activity of flavonoids and related compounds. | 2000 Jul |
|
Highly enantioselective construction of fused pyrrolidine systems that contain a quaternary stereocenter: concise formal synthesis of (+)-conessine. | 2004 May 3 |
|
Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf. | 2005 May 16 |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series. | 2007 Apr |
|
Antibacterial activities of the extracts and conessine from Holarrhena floribunda G. Don. (Apocynaceae). | 2007 Feb 16 |
|
Steroidal alkaloids from Holarrhena antidysenterica (L.) WALL. | 2007 Jun |
|
A new family of H3 receptor antagonists based on the natural product Conessine. | 2008 Feb 15 |
|
High-performance thin layer chromatography method for estimation of conessine in herbal extract and pharmaceutical dosage formulations. | 2008 Jan 22 |
|
Novel H3 receptor antagonists with improved pharmacokinetic profiles. | 2008 Jul 15 |
|
Chromatographic analysis of Kutajarista--an ayurvedic polyherbal formulation. | 2008 Jul-Aug |
|
Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells. | 2008 Jun 6 |
|
Development and validation of a visible absorption densitometry method for quantitation of conessine in Holarrhena antidysenterica (Kurchi). | 2008 Mar-Apr |
|
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. | 2008 Sep 11 |
|
Acute cardiac toxicity of nerium oleander/indicum poisoning (kaner) poisoning. | 2010 Oct |
|
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. | 2015 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23758861
Mice: Conessine significantly reduced parasitaemia (at 10 mg/kg exhibited 88.95% parasite inhibition) in P. berghei-infected mice. Conessine was administered orally to mice of different groups for four days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23758861
Conessine showed in vitro anti-plasmodial activity with its IC₅₀ value 1.9 ug/ml and 1.3 ug/ml using schizont maturation and pLDH assay respectively. The compound showed cytotoxity IC₅₀= 14 ug/ml against L6 cells of rat skeletal muscle myoblast.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C221
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
27965
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
208-897-2
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
546-06-5
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL191703
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
EZ38J9BBDF
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
441082
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
SUB06803MIG
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
C007111
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
C79899
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
119994
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
CONESSINE
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
443
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
m3750
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID6046000
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY | |||
|
100000084247
Created by
admin on Sat Dec 16 17:05:24 GMT 2023 , Edited by admin on Sat Dec 16 17:05:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)